1. Home
  2. Labeler Index
  3. State Of Florida Doh Central Pharmacy
  4. 53808-0831
  5. Product Images: Divalproex Sodium

Product Images Divalproex Sodium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Divalproex Sodium NDC 53808-0831 by State Of Florida Doh Central Pharmacy, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Divalproex Sodium Extend-release Tablets, USP 500 mg Bottle Label - Divalpoex Sod 500mg Mylan

Divalproex Sodium Extend-release Tablets, USP 500 mg Bottle Label - Divalpoex Sod 500mg Mylan

Divalproex Structural Formula - fd4949b2 1af2 4725 899f f54cc5cd2db6 01

Divalproex Structural Formula - fd4949b2 1af2 4725 899f f54cc5cd2db6 01

proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo - fd4949b2 1af2 4725 899f f54cc5cd2db6 02

proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo - fd4949b2 1af2 4725 899f f54cc5cd2db6 02

This document appears to be a graph or chart displaying the percentage reduction in CPS rate between patients who received Divalproex Sodium Delayed-Release and a placebo. The chart displays three categories: Improvement, No Change, and Worsening, and indicates that 50% of patients experienced improvement when treated with Divalproex Sodium Delayed-Release.*

proportion of patients achieving any particular level of reduction was consistently higher for high dose valproate than for low dose valproate - fd4949b2 1af2 4725 899f f54cc5cd2db6 03

proportion of patients achieving any particular level of reduction was consistently higher for high dose valproate than for low dose valproate - fd4949b2 1af2 4725 899f f54cc5cd2db6 03

The text includes a chart with the percentage reduction in CPS rate for different medications, along with a graph showing the percentage of patients who experience improvement, no change or worsening with High and Low Dose Divalproex Sodium Delayed Release medication. No further information is available.*

Figure 3 Mean Reduction in 4-Week Migraine Headache Rates - fd4949b2 1af2 4725 899f f54cc5cd2db6 04

Figure 3 Mean Reduction in 4-Week Migraine Headache Rates - fd4949b2 1af2 4725 899f f54cc5cd2db6 04

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.